Rigel Pharmaceuticals, Incorporated

Eli Lilly and Company

Vanessa Taylor

Rajinder Paul Singh

Hui Li

Yan Chen

Somasekhar Bhamidipati

Kin Tso

Rose Yen

Ankush Argade

Esteban Masuda

Sambaiah Thota

David Carroll

Simon Shaw

Thilo J Heckrodt

Darren J McMurtrie

Jeffrey Clough

Arvinder Sran

Robin Cooper

Pingyu Ding

Ihab S Darwish

Holger Keim

Jiaxin Yu

Brian Wong

Ryan Kelley

Jack Maung

Zhushou Luo

Vadim Markovtsov

Rao Kolluri

John McLaughlin

Sacha Holland

Dane A Goff

Donald G Payan

Matt Duan

Dazhong Fan

Lu Chou

John Yudhistir Ramphal

Andy Atuegbu

Mark Irving

Mark Markovtsov

Darren John Mcmurtrie

Darren Mcmurtrie

Rajinder Singh

Kyle Defrees

Avinder Sran

Vadim M V Markovtsov

Chi Young

Sarkiz Issakani

Dane Goff

Sambaiah Thhota

Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.

Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I. The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

Method for treating a disease or condition using a pyrazole compound or formulation thereof

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 kinase inhibitors

RIP1K inhibitors

RIP1 inhibitory compounds and methods for making and using the same

Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Benzazole compounds and methods for making and using the compounds

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

IRAK inhibitors and method for making and using

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Amide compounds and method for making and using

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Growing community of inventors

San Francisco, CA, United States of America

Vanessa Taylor